KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Idexx Laboratories (IDXX) over the last 17 years, with Q3 2025 value amounting to $7.7 million.

  • Idexx Laboratories' Change in Receivables rose 12861.98% to $7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.8 million, marking a year-over-year decrease of 112.27%. This contributed to the annual value of $28.3 million for FY2024, which is 4750.42% down from last year.
  • Per Idexx Laboratories' latest filing, its Change in Receivables stood at $7.7 million for Q3 2025, which was up 12861.98% from $29.6 million recorded in Q2 2025.
  • Idexx Laboratories' Change in Receivables' 5-year high stood at $54.7 million during Q1 2021, with a 5-year trough of -$27.8 million in Q4 2024.
  • For the 5-year period, Idexx Laboratories' Change in Receivables averaged around $12.6 million, with its median value being $7.7 million (2025).
  • In the last 5 years, Idexx Laboratories' Change in Receivables skyrocketed by 50515.7% in 2022 and then tumbled by 395349.85% in 2024.
  • Idexx Laboratories' Change in Receivables (Quarter) stood at -$15.9 million in 2021, then soared by 139.83% to $6.3 million in 2022, then crashed by 110.83% to -$686000.0 in 2023, then tumbled by 3953.5% to -$27.8 million in 2024, then skyrocketed by 127.68% to $7.7 million in 2025.
  • Its Change in Receivables was $7.7 million in Q3 2025, compared to $29.6 million in Q2 2025 and $45.2 million in Q1 2025.